(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 101.1MM | -6% |
Gross Profit | 29.1MM | -19% |
Cost Of Revenue | 72.1MM | +1% |
Operating Income | -4.6MM | +15% |
Operating Expenses | 33.6MM | -16% |
Net Income | -6.3MM | -34% |
R&D | 10.9MM | -29% |
G&A | 12.4MM | -6% |
Marketing | 10.3MM | -9% |
Amortization | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Accuray ( NASDAQ:ARAY ) Third Quarter 2024 Results Key Financial Results Revenue: US$101.1m (down 14% from 3Q 2023...
Accuray Incorporated (NASDAQ:ARAY) Q3 2024 Earnings Call Transcript May 1, 2024 Accuray Incorporated misses on earnings expectations. Reported EPS is $-0.06 EPS, expectations were $-0.013. ARAY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the […]
Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.
Q3 2024 Accuray Inc Earnings Call
Despite facing significant headwinds, Accuray showcases strategic initiatives aimed at long-term growth and market expansion.
Comprehensive Analysis of Accuray's Latest Earnings and Financial Health
Accuray (ARAY) delivered earnings and revenue surprises of -500% and 11.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024.
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, GKOS, SRDX and ARAY are placed ahead of their earnings releases.
Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024. The latest generation CyberKnife® and Radixact® platforms provide medical care teams with the technology necessary for expanding the curative power of radiation therapy and delivering on the focus of this year's congress, bridging the care gap. The European Society for Radiotherapy and Oncology's (ESTRO) annual me